Praxis Precision Medicines is a biotechnology company studying an investigational treatment for early onset SCN2A related epilepsy. Although Praxis is in the early stages of preclinical testing, if the data is positive, they intend to initiate clinical trials as quickly as possible.
Praxis Precision Medicines, in collaboration with Continuum Clinical, is fielding this family survey to help gather important information for their clinical trials. Having a clearer picture of what children with mutations in the SCN2A gene are like will help us ask better questions and design better clinical trials. Praxis will use the information gathered solely to advance this purpose, and for no other objective.
This survey will take no longer than 15 minutes to complete. You will be asked several questions about your child’s gene mutation and may want to have your child’s genetic report available for reference.
Press "Continue" to proceed.